(Q38103578)

28 August 2017

title

Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies (English)

1 reference

28 August 2017

1 reference

Tea Reljic

2

0 references

Ali Bazarbachi

object named as

Ali Bazarbachi

5

0 references

Benjamin Djulbegovic

6

object named as

Benjamin Djulbegovic

1 reference

28 August 2017

Najla El-Jurdi

1

1 reference

28 August 2017

Ambuj Kumar

3

1 reference

28 August 2017

Joseph Pidala

4

1 reference

28 August 2017

Mohamed A Kharfan-Dabaja

7

1 reference

28 August 2017

publication date

1 May 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

5

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

457-466

1 reference

Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation

28 August 2017

cites work

1 reference

Meta-analysis in clinical trials

21 January 2018

1 reference

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study

21 January 2018

1 reference

Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).

21 January 2018

1 reference

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

21 January 2018

1 reference

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

21 January 2018

1 reference

Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells

21 January 2018

1 reference

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.

21 January 2018

1 reference

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation

21 January 2018

1 reference

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

21 January 2018

1 reference

Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation

21 January 2018

1 reference

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

21 January 2018

1 reference

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation

21 January 2018

1 reference

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.

21 January 2018

1 reference

Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation

21 January 2018

1 reference

T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma

21 January 2018

1 reference

Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.

21 January 2018

1 reference

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

21 January 2018

1 reference

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.

21 January 2018

1 reference

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.13.31

1 reference

28 August 2017

1 reference